PHARMING GROUP NV (PHARM.AS) Stock Fundamental Analysis
Europe - AMS:PHARM - NL0010391025 - Common Stock
1.145 EUR
-0.01 (-1.04%)
Taking everything into account, PHARM scores 5 out of 10 in our fundamental rating. PHARM was compared to 73 industry peers in the Biotechnology industry. PHARM has only an average score on both its financial health and profitability. PHARM has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PHARM had negative earnings in the past year.
PHARM had a positive operating cash flow in the past year.
In multiple years PHARM reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: PHARM reported negative operating cash flow in multiple years.
1.2 Ratios
PHARM's Return On Assets of -1.84% is fine compared to the rest of the industry. PHARM outperforms 69.86% of its industry peers.
The Return On Equity of PHARM (-3.42%) is better than 75.34% of its industry peers.
PHARM has a better Return On Invested Capital (5.13%) than 80.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.84% | ||
| ROE | -3.42% | ||
| ROIC | 5.13% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 7.21%, PHARM is in the better half of the industry, outperforming 78.08% of the companies in the same industry.
PHARM has a Gross Margin of 89.31%. This is amongst the best in the industry. PHARM outperforms 82.19% of its industry peers.
In the last couple of years the Gross Margin of PHARM has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.21% | ||
| PM (TTM) | N/A | ||
| GM | 89.31% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
PHARM has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PHARM has more shares outstanding
The number of shares outstanding for PHARM has been increased compared to 5 years ago.
PHARM has a better debt/assets ratio than last year.
2.2 Solvency
PHARM has an Altman-Z score of 0.82. This is a bad value and indicates that PHARM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PHARM (0.82) is comparable to the rest of the industry.
PHARM has a debt to FCF ratio of 4.26. This is a neutral value as PHARM would need 4.26 years to pay back of all of its debts.
PHARM has a better Debt to FCF ratio (4.26) than 79.45% of its industry peers.
A Debt/Equity ratio of 0.50 indicates that PHARM is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.50, PHARM is in line with its industry, outperforming 52.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.26 | ||
| Altman-Z | 0.82 |
ROIC/WACC0.88
WACC5.83%
2.3 Liquidity
PHARM has a Current Ratio of 2.79. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PHARM (2.79) is better than 61.64% of its industry peers.
PHARM has a Quick Ratio of 2.07. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PHARM (2.07) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.00% over the past year.
PHARM shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.44%.
Measured over the past years, PHARM shows a quite strong growth in Revenue. The Revenue has been growing by 10.64% on average per year.
EPS 1Y (TTM)35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
Revenue 1Y (TTM)22.44%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%25.79%
3.2 Future
PHARM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 61.94% yearly.
Based on estimates for the next years, PHARM will show a quite strong growth in Revenue. The Revenue will grow by 9.43% on average per year.
EPS Next Y308.75%
EPS Next 2Y134.62%
EPS Next 3Y79.43%
EPS Next 5Y61.94%
Revenue Next Year18.75%
Revenue Next 2Y15.45%
Revenue Next 3Y15.46%
Revenue Next 5Y9.43%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PHARM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 21.13 indicates a rather expensive valuation of PHARM.
PHARM's Price/Forward Earnings ratio is rather cheap when compared to the industry. PHARM is cheaper than 82.19% of the companies in the same industry.
PHARM is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.88, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.13 |
4.2 Price Multiples
97.26% of the companies in the same industry are more expensive than PHARM, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, PHARM is valued cheaply inside the industry as 98.63% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.03 | ||
| EV/EBITDA | 1.51 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PHARM's earnings are expected to grow with 79.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y134.62%
EPS Next 3Y79.43%
5. Dividend
5.1 Amount
No dividends for PHARM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AMS:PHARM (10/28/2025, 5:29:56 PM)
1.145
-0.01 (-1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners14.71%
Inst Owner ChangeN/A
Ins Owners1.38%
Ins Owner ChangeN/A
Market Cap78.45M
Revenue(TTM)339.84M
Net Income(TTM)-8200000
Analysts87.69
Price Target7.32 (539.3%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.45%
Min EPS beat(2)-42.39%
Max EPS beat(2)123.3%
EPS beat(4)2
Avg EPS beat(4)19%
Min EPS beat(4)-42.39%
Max EPS beat(4)123.3%
EPS beat(8)3
Avg EPS beat(8)-53.99%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)11.02%
Min Revenue beat(2)8.68%
Max Revenue beat(2)13.37%
Revenue beat(4)3
Avg Revenue beat(4)6.98%
Min Revenue beat(4)-5.54%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)2.17%
Revenue beat(12)6
Avg Revenue beat(12)-0.82%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.49%
PT rev (3m)17.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)96.67%
EPS NY rev (1m)0%
EPS NY rev (3m)88.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.79%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)3.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 21.13 | ||
| P/S | 0.27 | ||
| P/FCF | 3.03 | ||
| P/OCF | 2.94 | ||
| P/B | 0.38 | ||
| P/tB | 0.88 | ||
| EV/EBITDA | 1.51 |
EPS(TTM)-0.01
EYN/A
EPS(NY)0.05
Fwd EY4.73%
FCF(TTM)0.38
FCFY33%
OCF(TTM)0.39
OCFY34%
SpS4.26
BVpS3
TBVpS1.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.84% | ||
| ROE | -3.42% | ||
| ROCE | 6.84% | ||
| ROIC | 5.13% | ||
| ROICexc | 7.92% | ||
| ROICexgc | 19.07% | ||
| OM | 7.21% | ||
| PM (TTM) | N/A | ||
| GM | 89.31% | ||
| FCFM | 8.87% |
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score6
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 4.26 | ||
| Debt/EBITDA | 2.95 | ||
| Cap/Depr | 5.84% | ||
| Cap/Sales | 0.27% | ||
| Interest Coverage | 3.72 | ||
| Cash Conversion | 77.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.79 | ||
| Quick Ratio | 2.07 | ||
| Altman-Z | 0.82 |
F-Score6
WACC5.83%
ROIC/WACC0.88
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
EPS Next Y308.75%
EPS Next 2Y134.62%
EPS Next 3Y79.43%
EPS Next 5Y61.94%
Revenue 1Y (TTM)22.44%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%25.79%
Revenue Next Year18.75%
Revenue Next 2Y15.45%
Revenue Next 3Y15.46%
Revenue Next 5Y9.43%
EBIT growth 1Y248.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year279.47%
EBIT Next 3Y79.88%
EBIT Next 5Y88.46%
FCF growth 1Y288.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y313.32%
OCF growth 3YN/A
OCF growth 5YN/A
PHARMING GROUP NV / PHARM.AS FAQ
What is the ChartMill fundamental rating of PHARMING GROUP NV (PHARM.AS) stock?
ChartMill assigns a fundamental rating of 5 / 10 to PHARM.AS.
Can you provide the valuation status for PHARMING GROUP NV?
ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHARM.AS). This can be considered as Fairly Valued.
Can you provide the profitability details for PHARMING GROUP NV?
PHARMING GROUP NV (PHARM.AS) has a profitability rating of 4 / 10.
Can you provide the financial health for PHARM stock?
The financial health rating of PHARMING GROUP NV (PHARM.AS) is 5 / 10.
What is the earnings growth outlook for PHARMING GROUP NV?
The Earnings per Share (EPS) of PHARMING GROUP NV (PHARM.AS) is expected to grow by 308.75% in the next year.